Next Phase Newsletter

A Venture Capital company based the southeast USA manages several funds, with its most recent fund having had its first close in 2017. The firm looks to provide up to $3-4 million of preferred equity capital in the initial round and up to $6 million over the life of the investment. The firm is very flexible in terms of period to exit but generally looks to exit in around 5 years. The firm will consider companies globally.

The firm is currently looking for companies developing Therapeutics and Medical Technology. Within therapeutics, which is the firm’s primary focus, companies with an asset anywhere from pre-clincal with positive animal data to phase II will be considered. The firm is generally open to all technology types and indications with the exception of wound care and psychiatry. Within devices, the firm is currently looking for market approved product with early revenue; however, devices are not an investment priority at present. The firm is looking for companies targeting true un-met medical needs where either no treatment currently exists or the existing standard of care is wrought with side-effects and other impediments to quality care.

The firm does not have any specific requirement for a firm’s management team although they are an active investor looking to take a seat on the company’s board. The firm generally tends to lead or co-lead investments into selected companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family investment trust based in the Boston area invests in early-stage healthcare and life sciences startups. The firm makes seed investments usually in the range of $50K-$250K initially and typically participates in future financing rounds. Investments may come in the form of straight equity or convertible notes depending on the deal. In addition to capital, the group looks to leverage years of experience in the biotech and healthcare industry and add value to portfolio companies through clinical and regulatory strategy, product launch and commercial strategy as well as corporate governance. The group may lead or syndicate rounds and is open to companies on a global basis.

The firm is fairly agnostic in terms of sectors and indications and is interested in therapeutics, medical devices, diagnostics and healthcare IT. As for therapeutics, the group is only interested in first-in-class / best-in-class compounds and does not evaluate iterative or repurposed assets (such as 505(b)(2) regulatory pathways). The group is also interested in medical devices and diagnostic technologies and has specific expertise in the orthopedic space, where several of the groups investments lie. Healthcare IT is also a focus area with most interest in consumer-oriented digital therapies, as opposed to enterprise software solutions.

The firm places a large emphasis on the management team / founders and looks to completely understand the company’s business prior to investment. The group often seeks a board seat along with an investment, but it is not necessarily required

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global venture capital firm based in Menlo Park, California with additional offices worldwide has approximately $3.5 billion in total assets across 10 funds, and the most recent fund closed at over $600 million. The firm focuses on making equity investments into the life science and technology spaces from seed to late venture stage. The investment size is varied, and typically it ranges from $1 million to $20 million. The firm will invest in companies based in the US, India and Israel.

The firm is currently looking for new opportunities in the Biotech Therapeutics, Medical Devices and Healthcare IT sectors. The firm will also consider Diagnostics, but that will not be its focus. For Therapeutics and Medical Devices, the firm is extremely opportunistic in terms of subsectors and indications. The firm is interested in companies targeting orphan diseases. The firm is generally looking for companies in the clinical stage of development, but it also considers preclinical companies one or two years from clinics, as well as near companies near commercial stages dependent on the case.

The firm primarily invests in private companies, and considers pre-revenue companies. The firm doesn’t have specific requirements for company’s management team or revenue.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A VC firm with offices in California, Beijing, and Hong Kong manages over 100 portfolio companies in the US and China. The firm generally invests in the early stages, mostly in seed and Series A rounds. The firm focuses its investments in U.S. and China, but also considers companies based in Canada.

In the life sciences sector, the firm will consider medical technology, diagnostic, and healthcare IT companies. The firm is open to all types of medical technology in all types of indications, and will look at both 510k and PMA medical devices in development or clinical trials. Previously, the firm has also invested in the synthetic engineering space.

The firm is looking for early-stage companies with a highly innovative product. The management team of potential portfolio companies is expected to be committed to the company full-time and will have a track of strong, successful entrepreneurship. The firm does not require a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office has a healthcare focused investment arm based in New York. The firm is interested in global companies, but is currently more focused on the US, Canada, Europe, and Israel regions. The firm makes investments ranging from $5 – $80 million. The firm is open to both leading and co-investing. The firm prefers investing in companies that have demonstrated clinical data and is currently not limited in the number of investments they plan to make this year.

The firm is interested in therapeutics, medical devices, and diagnostics. The firm is agnostic to the types of therapeutics, devices, and diagnostics they look to invest in. The firm is most interested in highly differentiable products that address unmet medical needs.

The firm looks for experienced management teams and depending on the deal, may or may not seek a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture / life science investment arm of a life science and medical equipment manufacturer invests from an evergreen fund. The firm prefers to invest at company formation / seed stage, but no later than Series A. Typical investments range from USD1-5M, but the fund will make larger tranched investments in case of therapeutic opportunities. The firm invests in companies worldwide. The firm can act as either a lead or a co-investor role. The firm prefers to invest at company formation or seed stages, with the latest stage they will invest being Series A.

The firm has four current focus areas: women’s health/fertility, life sciences tools & diagnostics, biotech (novel therapeutics), and PMA medical devices. The firm is interested broadly across all indications within these sectors.

The firm prefers to invest in teams with a strong track record, but has also worked with first-time entrepreneurs. The firm may or may not take a board seat in a portfolio company. If a company is seeking to expand into Asia, the firm can leverage the capabilities of its parent company to help companies with regulatory affairs, market access and distribution, especially in the life sciences tools and fertility markets.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Palo Alto, CA is looking for early stage life science opportunities. The firm also has a partner in China that can provide support to companies interested in China market entry, but companies do not need to have a China angle. The firm has great experience with working with regulatory agencies to gain product approval for both FDA and CFDA. Since its establishment, the firm has invested in a total of 13 companies and continues to actively seek life science investments, aiming to invest in 8-10 companies per year. The firm usually participates in seed to series B financing rounds with check sizes between $500K – 2M and will consider companies based in USA and China.

The firm is opportunistic and will consider all early-stage opportunities in therapeutics, medical devices, diagnostics, and healthcare IT, as long as the technology is considered highly disruptive. The firm’s greatest focus lies in the medical device sector in which the firm has the strongest expertise. In therapeutics, the firm will consider pre-clinical and phase I assets. In medical devices and diagnostics, the firm is open to all classes of medical devices including 510k and PMA that are in development or clinical trials. The firm has reviewed companies of various stages in the past: those that have just developed a valid prototype, and those that were already profitable prior to investment.

The firm seeks to work with companies with an experienced management team, ideally led by a serial entrepreneur with a successful track record. The firm can both lead and co-invest but prefers to lead financing rounds for medical device companies and will most likely take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com